The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline

                                       
Regulated information
May 14, 2025 – 7:45 a.m. CET
        
The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline

• Group performance: continued success of the strategic transformation
  • Improved sales mix between growth engines and mature businesses and good cost control compensated for the negative impact of the market decline for traditional film
  • Adjusted EBITDA stable versus last year at 2 million euro in a seasonally weaker quarter
• HealthCare IT success: strong Q1 and continued successful transition to cloud-enabled Enterprise Imaging
  • 63% increase in 12 months rolling order intake, of which a high share net new customers and cloud related contracts
  • Top line increased by 12.0% versus Q1 2024 to 57 million euro
  • Adjusted EBITDA rose from 1.3 million euro in Q1 2024 to 5.0 million euro
• Digital Print & Chemicals growth: step up in revenue and profitability
  • 5.8% top line growth versus Q1 2024 to 97 million euro, mainly driven by Specialty Films & Chemicals
  • Green Hydrogen Solutions and Digital Printing Solutions reported a slower quarter
  • In printing, ink sales grew by 16% versus Q1 2024, but equipment was impacted by a weaker investment climate
  • Adjusted EBITDA increased from 1.0 million euro in Q1 2024 to 2.3 million euro
• Challenges in Radiology Solutions: seasonally weak quarter – strong impact of the decline of the medical film markets, particularly in China
  • Mid-teens percentage revenue decline versus Q1 2024 further impacting profitability
  • Savings related to the plan to optimize the cost base of the traditional film activities on track and expected to kick in as from the second half of 2025

Mortsel (Belgium), May 14, 2025 – 7:45 a.m. CET – Agfa-Gevaert today commented on its results in the first quarter of 2025.

“The first quarter of 2025 was marked by the continued strong performance of our HealthCare IT division, driven by customer adoption of our leading cloud technology. While our Digital Printing Solutions equipment business faced challenges due to economic uncertainty, and the market for our ZIRFON membranes for green hydrogen production slowed down in Europe and North America, the long-term outlook for these businesses remains promising. We are actively addressing the decline in traditional film markets through our cost optimization program, with initial savings expected in the second half of 2025.”
Pascal Juéry, President and CEO of the Agfa-Gevaert Group.

(*)         Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to ‘Results from operating activities’ (EBIT)/EBITDA

Definitions of non-IFRS financial measures (APMs): see page 8.
The consolidated statements are included at the end of this press release. They are an integral part of this document.

Agfa-Gevaert Group

(*)         before adjustments and restructuring expenses
(**)         Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to ‘Results from operating activities’(EBIT)/EBITDA

First quarter

• The HealthCare IT division achieved a strong top and bottom line step up versus the first quarter of 2024. Digital Print & Chemicals also improved both its revenue and profitability. The Group’s revenue decline is due to the accelerated decline of the medical film markets, which affected the Radiology Solutions division. The increased economic uncertainty also had an impact on the investment climate for Digital Printing Solutions.
• Driven by the growth engines (particularly HealthCare IT) and by positive product/mix effects – and in spite of the lower fixed cost coverage in the traditional film activities, the Group’s gross profit margin improved to 30.7% of revenue.
• Due to strict cost control, operating expenses amounted to 81 million euro, versus 84 million euro in the first quarter of 2024.
• Adjusted EBITDA amounted to 2 million euro (0.9% of revenue). Profitability was mainly impacted by the effects of the market decline for the medical film activities.
• Adjustments and restructuring expenses resulted in a charge of 2 million euro, which is in line with Q1 2024.
• The net finance costs remained stable at 6 million euro.
• Income tax expenses increased from 0 million euro to 6 million euro. Income taxes in Q1 2024 were driven by a deferred tax income.
• The Agfa-Gevaert Group posted a net loss of 20 million euro.

Financial position and cash flow

• Working capital evolved from 29% in Q4 2024 to 32%. In absolute numbers, working capital increased from 335 million euro at the end of 2024 to 358 million euro, mainly driven by inventories.
• The Q1 free cash flow was minus 27 million euro, mainly influenced by the increase in working capital (inventories) and the investment in the ZIRFON plant. Cash-in from provisions & other was more favorable thanks to the build down of the lease receivables and the income tax cash-in was related to R&D tax credits. Pension cash-out and cash-out for Adjustments and restructuring items were in line with last year.
• Net financial debt (excluding IFRS 16) evolved from 37 million euro in Q4 2024 to 72 million euro. Currently, the revolving credit facility totals 230 million euro, maturing in May 2026. At the end of Q1, although no testing is required from financial institutions, the leverage ratio (net debt/adjusted EBITDA) was 1.4 versus covenants of maximum 3. The interest coverage ratio (adjusted EBITDA/interest expense) was at 11.1 versus covenants of minimum 5.

Outlook
The Agfa-Gevaert Group expects that the growth engines will continue to perform strongly in 2025. As usual, due to seasonality reasons, a slower start of the year is expected, followed by a stronger second half. This outlook is based on the current economic environment.

2025 outlook per division:

• HealthCare IT: The good order intake momentum is expected to continue. The division’s performance is expected to improve compared to that of last year.
• Digital Print & Chemicals: The division expects growth in top line and profitability, driven by Digital Printing Solutions. Given the current situation of the market, a stable performance is expected for Green Hydrogen Solutions.
• Radiology Solutions: A continuation of the declining trend in sales and profitability is expected. The savings related to the program to adjust the cost base of the traditional film activities are expected to kick in as from the second half of 2025.

A part of the outstanding receivable in connection with the sale of the Offset Solutions division to Aurelius Group is still under discussion. The issue has been submitted to an independent expert, who will have to establish the final purchase price.

HealthCare IT

(*)         Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to ‘Results from operating activities’(EBIT)/EBITDA

First quarter

• HealthCare IT’s momentum that started to build in the course of 2024 continued in the first months of 2025. Mainly based on cloud-related contracts with high-profile new customers, HealthCare IT recorded a 63% increase in the 12 months rolling order intake starting from 114 million euro the year before to 186 million euro. 15% of Q1 order intake is cloud-related. Net new customers represent 29% of Q1 order intake. 64% of Q1 order intake is related to project contracts and 36% to recurring revenue contracts.
• The division’s top line improved by 12.0% versus Q1 2024. Recurring revenue grew by 4% and now amounts to 61% of the total revenue.
• Mainly due to the increased service contribution and a higher contribution of own IP software in total sales, HealthCare IT’s gross profit margin improved strongly from 43.8% in Q1 2024 to 47.9%. The adjusted EBITDA margin evolved from 2.5% to 8.8%.
• Increasing shift towards Cloud technology fuels strong momentum for Agfa’s Enterprise Imaging Cloud:
  • Contract with Englewood Health to deploy the Enterprise Imaging Cloud solution at one of New Jersey’s leading healthcare systems – now live.
  • New Enterprise Imaging Cloud engagement in Alaska.
  • Enterprise Imaging Cloud SaaS agreement with a private clinic group in Alberta, Canada.
• Agfa HealthCare recognized for excellence in innovation and customer service at the 2025 HIMSS Best in KLAS Awards:
  • Enterprise Imaging XERO Viewer ranked #1 Best in KLAS in the Universal Viewer category for the second consecutive year.
  • Enterprise Imaging VNA ranked #1 Best in KLAS in the Vendor Neutral Archive category.
  • Agfa HealthCare received the 2025 Best in KLAS Most Improved Software award.
  • Enterprise Imaging for Radiology earned the number 2 spot in Best in KLAS USA for overall performance across both small- and large-volume organizations.
  • In its latest 2025 US PACS report, KLAS highlighted: “Both large- and small-volume customers of Agfa HealthCare see them as a strong, proactive partner who understands customers’ needs and unique environments.”

Digital Print & Chemicals

(*)         Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to ‘Results from operating activities’(EBIT)/EBITDA

First quarter
Division performance

• The Digital Print & Chemicals division’s top line grew by 5.8%, mainly driven by the activities in de field of Specialty Films & Chemicals. Green Hydrogen Solutions and Digital Printing Solutions reported a slower quarter, the latter also impacted by a weaker investment climate.
• Mainly due to unfavorable mix effects, the division’s gross profit margin evolved from 29.3% of revenue in Q1 2024 to 27.9% of revenue.
• Mainly thanks to strict control of operating expenses, the division’s adjusted EBITDA margin increased.

Digital Printing Solutions

• Following the record Q4 2024, the Digital Printing Solutions business reported a slower start to the year, partly due the increased economic uncertainty. The top line decreased by almost 3% versus Q1 2024.The business’ profitability improved slightly versus Q1 2024.
• The business’ order book shows good traction based on the interest in recently launched solutions.
• In 2025, Agfa expects to build further momentum with its digital printing portfolio for the Sign & Display market segment, based on the new product launches and the global strategic partnership between Agfa and EFI for digital printing equipment.
• Furthermore, Agfa made solid progress in the industrial and packaging segment of the market. This business will start to contribute as of 2025. Recently, Agfa signed a multi-year contract with BHS Corrugated for the exclusive delivery of single pass water-based corrugate printers and ink supply.
• Ink top line grew by 16%, driven by the success of the ongoing program to convert former Inca customers to Agfa’s ink sets, growing OEM ink volumes, ink sales related to the partnership with EFI and good traction on the water based décor inks.
• Agfa continues to expand and enhance its industry-leading digital printing equipment portfolio in both the Sign & Display segment and the industrial and packaging segment of the market.
  • In April, Agfa expanded its Anapurna Ciervo family with the new Ciervo H2050 model and introduced the Ciervo H2500 printer to the North American market at ISA International Sign Expo 2025.
  • In May, Agfa launched new high-performance inkjet printing solutions at the FESPA trade show in Berlin:
    • Onset Panthera FB3216: the only true flatbed high-productivity inkjet printer on the market.
    • Jeti Tauro H3300 XUHS: the fastest printer in the Tauro family of hybrid machines.
  • First installation of a BHS Jetliner MCP in Q1, first installation of a Jetliner XC foreseen for the second half of the year.
  • The beta test phase of the first SpeedSet single-pass water based packaging printer is being finalized.

Green Hydrogen Solutions

• Sales of the ZIRFON membranes for renewable-powered green hydrogen production decreased by about 18% versus Q1 2024.
• Further consolidation is expected among Western European electrolyzer manufacturers.
• Recently, Western markets slowed down as legislation is still too complex or being clarified. Markets in the Middle East, Africa and Asia show more momentum and an increasing focus on high performing systems (using composite materials like ZIRFON).
• The establishment of a new industrial-scale ZIRFON production plant in Mortsel, Belgium is on track. This plant will come into operation in October 2025.

Radiology Solutions

(*)         Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to ‘Results from operating activities’(EBIT)/EBITDA

First quarter

• The decline of Agfa’s medical film volumes continued, following the overall market trends. Profitability in this business was impacted by the volume decrease and costs related to the manufacturing footprint. This was partly offset by measures to control costs and to streamline the business. The gross profit margin of the division decreased from 26.3% of revenue in Q1 2024 to 24.0%. The adjusted EBITDA margin decreased from minus 0.9% of revenue in Q1 2024 to minus 6.1%. The above mentioned program to tackle the challenges in the film business is on track. Early April, Agfa announced that it decided to shut down its film finishing site in Bushy Park in South Carolina, USA in order to consolidate its finishing activities mainly at the Mortsel site in Belgium. The program is expected to deliver its first results as from the second half of 2025.
• Agfa’s Direct Radiography (DR) business posted a 4.5% top line decrease, following a strong fourth quarter of 2024. The first quarter of 2024 was marked by the sales booked for several larger projects. The Computed Radiography (CR) business’ top line continued to decline. However, following targeted measures including the closure of a plant in Schrobenhausen, Germany, profitability for this business improved considerably versus Q1 2024.
• For DR, Agfa expects the momentum to pick up again in the coming quarters, partly based on recent major orders. Primary Health Care Corporation of Qatar (PHCC Qatar), for instance, has chosen to purchase seven DR 600 ceiling-suspended X-ray rooms, including the SmartXR intelligent radiography workflow assistant. PHCC Qatar counts more than 30 health centers in the country.

Contractor Operations and Services – former Offset

(*)         Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to ‘Results from operating activities’(EBIT)/EBITDA

• Early April 2023, the Agfa-Gevaert Group completed the sale of its Offset Solutions division to Aurelius Group. The division contains results related to supply and manufacturing agreements that the Agfa-Gevaert Group signed with its former division, now rebranded as ECO3.

Conference call for analyst and investors
Pascal Juéry, CEO of the Agfa-Gevaert Group, and Fiona Lam, CFO, will present the Q1 2025 results to analysts and investors at 11:00 a.m. CET on Wednesday, May 14. This presentation can be accessed live upon registration via the agfa.com website and will be available on the website after the event.

End of message

Definitions of non-IFRS financial measures (APMs)

• Adjusted EBIT: The result from continuing operating activities before restructuring expenses and adjustments.
• Adjusted EBITDA: The result from continuing operating activities before depreciation, amortization, restructuring expenses and adjustments.
• EBITDA: The result from continuing operating activities before depreciation and amortization.
• Gross profit (margin): Gross profit (margin) before adjustments and restructuring expenses.
• Restructuring expenses: Expenses related to detailed and formal restructuring plans approved by management. Related expenses comprise expenses recognized when accounting for a ‘Provision for restructuring’ but could also comprise other expenses that are directly linked to a formal restructuring plan (e.g. exceptional write-downs on inventories and impairment losses on receivables when specifically linked to / resulting from a decision to restructure). Restructuring expenses mainly relate to employee termination costs.
• Adjustments: Income and expenses related to activities or events which are not indicative as arising from normal, recurring business operations and are not related to a restructuring plan. These adjustments comprise expenses related to important transformation programs, material changes in the measurement estimates of assets or liabilities related to infrequent events (such as the sale of a building), material gains or losses related to infrequent events or transactions (e.g. mergers and acquisitions) as well as substantial litigations which are not part of the normal recurring business activities. In case the activities or events are not directly linked to a specific segment but are related to Agfa as a Group, the costs are not attributed to the reportable segments.
• Free Cash Flow: The sum of ‘Net cash from / (used in) operating activities’ and ‘Net cash from / (used in) investing activities excluding the impact of ‘Acquisitions of subsidiaries, net of cash acquired’, ‘Interests received’ and the ‘Net cash from / (used in) operating and investing activities that relates to discontinued operations’.
• Adjusted Free Cash Flow: Free Cash Flow ‘Adjusted’/ excluded for the impact of: the ‘Cash out for pensions below EBIT’, the ‘Cash out for long-term termination benefits’ and the cash out for ‘Adjustments and restructuring expenses’.
• Cash out for pensions below EBIT: The sum of Expenses for defined benefit plans & long-term termination benefits (see ‘Consolidated Statement of Cash Flows’) and the cash out for defined benefit plans & long-term termination benefits that are part of the ‘Cash out for employee benefits’ as presented in the Consolidated Statement of Cash Flows.
• Adjustments and restructuring cash in- and outflows: Cash in- and outflows resulting from income and expenses that are either in the current or previous reporting periods recognized in ‘Adjustments’ or ‘Restructuring expenses’.
• Working Capital: the sum of Inventories plus trade receivables plus contract assets minus contract liabilities and minus trade payables.
• Net financial debt incl IFRS 16: the sum of non-current and current liabilities to banks including non-current and current lease liabilities and excluding pension debt, and bank overdrafts minus cash and cash equivalents.
• Net financial debt excl IFRS 16: the sum of non-current and current liabilities to banks excluding non-current and current lease liabilities and excluding pension debt, including bank overdrafts minus cash and cash equivalents.
• Net debt: the sum of Net financial debt incl IFRS 16 and the liabilities for post-employment and long-term termination benefit plans – net balance sheet position.
• Leverage ratio: Net Financial debt excluding IFRS 16 and excluding pension debt/Adjusted EBITDA excluding IFRS 16 over the period of the last 12 months.
• Interest cover ratio: Adjusted EBITDA excluding IFRS 16 over the period of the last 12 months/Net interest expenses excluding IFRS 16 over the period of the last 12 months.
• Order intake: The financial value of all new orders accepted by Agfa HealthCare IT during the period, including Licenses, Implementation services, Hardware and/or Cloud computing, but excluding Support/Software Maintenance Agreements.
• Support/Software Maintenance Agreements (SMA): Service contracts entitling Agfa HealthCare IT Perpetual License customers to software updates and patches as well as service and support. Order Intake is not recorded for SMA contracts.
• Net new order intake: Order Intake accepted from customers who were not using Agfa HealthCare IT software prior to the order (aka “New Logo” sales). Usually with such an order the customer replaces a system from a competitor with a system from Agfa HealthCare IT.
• Cloud order intake: Order Intake accepted for deployments of Agfa HealthCare IT’s solution on a Cloud Computing infrastructure instead of the traditional deployment on dedicated Hardware on the customers premises (“on Premise”).
• Recurring order intake: Order Intake for services with a recurring transaction model (Revenue recognition over time as opposed to one-off). Examples include: License Subscriptions, Managed services, Cloud computing services, SaaS contracts).
• Project order intake: Order Intake for goods and services delivered and revenue recognized at a single point in time. Examples include: Perpetual Licenses, Implementation services, Hardware.

Contact:
Viviane Dictus
Director Corporate Communication
Septestraat 27
2640 Mortsel – Belgium
T +32 (0) 3 444 71 24
E [email protected]

The full press release and financial information is also available on the company’s website: www.agfa.com.

Consolidated Statement of Profit or Loss (in million euro)

Unaudited, consolidated figures following IFRS accounting policies.

Consolidated Statement of Comprehensive Income for the quarter ending March 2024 / March 2025 (in million euro)  
Unaudited, consolidated figures following IFRS accounting policies.

Consolidated Statement of Financial Position (in million euro)

Unaudited, consolidated figures following IFRS accounting policies.

Consolidated Statement of Net Debt (in million euro)

Unaudited, consolidated figures following IFRS accounting policies.

Consolidated Statement of Cash Flows (in million euro)
Unaudited, consolidated figures following IFRS accounting policies.

The Group has elected to present a statement of cash flows that includes all cash flows, including both continuing and discontinuing operations.

Consolidated Statement of changes in Equity (in million euro)
Unaudited, consolidated figures following IFRS accounting policies.

Reconciliation of non-IFRS information (in million euro)

(Adjusted) Free Cash Flow

Reconciliation of non-IFRS information (in million euro)

Adjusted EBIT

Working capital

Reconciliation of non-IFRS information (in million euro)

Net Financial Debt including IFRS 16

Net Financial Debt excluding IFRS 16

Attachment

• press release in pdf